Thromboxane receptor antagonist BMS-180291: A new pre-clinical lead

Raj N. Misra,Baerbel R. Brown,Philip M. Sher,Manorama Patel,Steven E. Hall,Wen-Ching Han,Joel C. Barrish,David M. Floyd,Peter W. Sprague,Richard A. Morrison,Richard E. Ridgewell,Ronald E. White,Gerald C. DiDonato,Don N. Harris,Anders Hedberg,William A. Schumacher,Maria L. Webb,Martin L. Ogletree

Thromboxane receptor antagonist BMS-180291: A new pre-clinical lead

1992

Raj N. Misra
Baerbel R. Brown
Philip M. Sher
Manorama Patel
Steven E. Hall
Wen-Ching Han
Joel C. Barrish
David M. Floyd
Peter W. Sprague
Richard A. Morrison
Richard E. Ridgewell
Ronald E. White
Gerald C. DiDonato
Don N. Harris
Anders Hedberg
William A. Schumacher
Maria L. Webb
Martin L. Ogletree

Abstract The synthesis and initial pharmacology of interphenylene 7-oxabicyclo[2.2.1]heptane oxazole thromboxane (TxA 2 ) receptor antagonist BMS-180291 is described. BMS-180291 has been characterized as an orally bioavailable, potent and selective TxA 2 antagonist with a long duration of action.

Keywords:

Receptor antagonist
Thromboxane
Antagonist
Biochemistry
Oxazole
Thromboxane receptor
Chemistry
short duration
thromboxane receptor antagonist
Bioavailability
Pharmacology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations